Auditory function after a prolonged course of ciprofloxacin-dexamethasone otic suspension in a murine model.
OBJECTIVE
To test for ototoxicity after prolonged ototopical fluoroquinolone use in the middle ear space using a murine model.


METHODS
Nonrandomized controlled trial.


METHODS
Twelve CBA/J mice.


METHODS
The mice received daily intratympanic injections of ciprofloxacin-dexamethasone otic suspension for 21 days. The contralateral ear received daily intratympanic injections of sterile isotonic sodium chloride solution (saline) as a control.


METHODS
Click-evoked auditory brainstem response (ABR) thresholds were obtained before injection and 10 days and 3 months after injection.


RESULTS
Mean (SEM) preinjection ABR thresholds were 47.17 (2.74) dB peak equivalent sound pressure level (peSPL) in ciprofloxacin-dexamethasone-treated ears and 45.08 (1.56) dB peSPL in saline-treated ears (P = .38). Mean (SEM) postinjection ABR thresholds in ciprofloxacin-dexamethasone-treated ears were 44.25 (1.25) dB peSPL after 10 days and 43.00 (1.51) dB peSPL after 3 months. Mean (SEM) postinjection ABR thresholds in saline-treated ears were 48.00 (1.51) dB peSPL after 10 days and 45.92 (1.79) dB peSPL after 3 months. There were no significant differences in ABR thresholds for ciprofloxacin-dexamethasone-treated ears (P = .29, P = .10) or saline-treated ears (P = .07, P = .59).


CONCLUSIONS
Ciprofloxacin-dexamethasone suspension did not cause either immediate or delayed ototoxicity after 21 days of intratympanic administration in the CBA/J mouse model.
Kavanagh
Katherine R
KR
Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Connecticut Health Center, Farmington, CT 06030, USA.
Parham
Kourosh
K
Schoem
Scott R
SR
D000208:Acute Disease; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage; D002939:Ciprofloxacin / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004338:Drug Combinations; D004432:Ear, Middle / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D007267:Injections; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D010033:Otitis Media / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013535:Suspensions; D013997:Time Factors; D016896:Treatment Outcome; D014432:Tympanic Membrane
D000890:Anti-Infective Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D013535:Suspensions; D002939:Ciprofloxacin; D003907:Dexamethasone